Modification: BACE1: Transgenic
Disease Relevance: Alzheimer's Disease
Strain Name: N/A
Genetic Background: C57BL/6 J
Wild-type human BACE driven by the murine Thy1 promoter.
These mice were generated to determine how BACE overexpression affects the processing of APP in vivo. Two transgenic lines were reported (BACE54/4 and BACE54/11) both expressing human BACE at high levels in the brain. Human BACE mRNA was approximately 4-fold higher than endogenous murine BACE mRNA. Highest expression of human BACE protein was measured in the cortex and hippocampus, lowest in the cerebellum.The transgenic animals had a significant reduction in the amount of full-length APP and increased levels of C99 and C89, the proteolytic products generated by β-secretase cleavage. Neuropatholgoy was not observed, and behavior was not assessed.
These mice have been breed to mice overexpressing APP, such as the huAPP751 line (wild-type or carrying the Swedish mutation). Bigenic animals showed significant reduction of full-length APP, as well as elevated C99, C89 and sAPPβ, Aβ40 and Aβ42 (Bodendorf et al., 2002).
- Bodendorf U, Danner S, Fischer F, Stefani M, Sturchler-Pierrat C, Wiederhold KH, Staufenbiel M, Paganetti P. Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid. J Neurochem. 2002 Mar;80(5):799-806. PubMed.
- Pastorino L, Ikin AF, Lamprianou S, Vacaresse N, Revelli JP, Platt K, Paganetti P, Mathews PM, Harroch S, Buxbaum JD. BACE (beta-secretase) modulates the processing of APLP2 in vivo. Mol Cell Neurosci. 2004 Apr;25(4):642-9. PubMed.